eGenesis

Barth most recently served as chief medical officer at Ascidian Therapeutics, where he helped build the clinical team.

Bergheiser has over 20 years of experience in the biopharmaceutical sector, spanning strategy, new product planning, and business development.

He was responsible for product development and regulatory affairs at Catabasis Pharmaceuticals, where he led clinical advancement.

She has 20 years of scientific research experience, including in vitro and in vivo pharmacology, DMPK, and toxicology across multiple therapeutic areas.

For general inquiries, media inquiries, and investor inquiries.

eGenesis develops human-compatible organs for transplantation.

eGenesis envisions a world where transplant is accessible to all patients who may benefit.

eGenesis reports that five patients with kidney failure have received EGEN-2784 kidney transplants through its Expanded Access study since March 2024. The company says the FDA-cleared Phase 1/2/3 RESTORE trial is expected in the first quarter of 2027.

Sep 2026 · eGenesisNews article

eGenesis appoints Glenn S. Vraniak as chief financial officer and Jennifer Bergheiser as chief commercial officer. Bergheiser is promoted to the role as the company’s clinical programs advance toward commercialization.

Jun 2026 · eGenesisNews article

eGenesis reports FDA clearance of an investigational new drug application for EGEN-2784, enabling a Phase 1/2/3 study in end-stage kidney disease. The company also reports that the first patient in its ongoing expanded access study has surpassed seven months without dialysis.

Sep 2025 · eGenesisNews article

eGenesis reports that a second living patient receives its genetically engineered porcine kidney, EGEN-2784, at Massachusetts General Hospital. The patient is discharged and off dialysis.

Feb 2025 · eGenesisNews article